

## Nanexa participates at the 4th annual "Beyond Medicines' Barriers Meeting", arranged by the International Myeloma Foundation

**On February 7-8, Nanexa participates in Lugano, Switzerland, as one of the sponsors at the 4th annual "Beyond Medicines' Barriers Meeting", arranged by the International Myeloma Foundation (IMF).**

The basis for the IMF "Beyond Medicine's Barriers" meeting is to leverage patients, patient advocates, researchers, health care professionals, health economists, societal representatives, myeloma experts, and pharmaceutical companies, and discuss and initiate ways to optimize the use of new medicines – balancing rising costs with increasing budgetary pressures and stimulating access to medicines.

The IMF is the first and largest global organization focusing specifically on multiple myeloma. The IMF's reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure of the disease.

"For Nanexa as a small pharmaceutical company with clinical development of a new medicine against multiple myeloma, it is very important to have the opportunity to participate at an international meeting of this kind. It is a good venue for us to discuss the question around the compliance and adherence to the medications that myeloma patients are treated with for their disease", says Bengt Gustavsson, Director Clinical Development and Medical Affairs at Nanexa.

**For additional information, please contact:**

---

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: [david.westberg@nanexa.se](mailto:david.westberg@nanexa.se)

[www.nanexa.com](http://www.nanexa.com)

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

## About Nanexa AB (publ)

---

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

## Attachments

---

[Nanexa participates at the 4th annual "Beyond Medicines' Barriers Meeting", arranged by the International Myeloma Foundation](#)